Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06989086 · ClinicalTrials.gov registry record · NA
FearLess in NeuroOncology
A NA study of Caregiver and Astrocytoma, sponsored by Virginia Commonwealth University.
- Recruiting
- Registry status
- NA
- Development phase
- 112
- Enrollment target
- 1
- Study location
NCT06989086: Recruiting NA study of Caregiver and Astrocytoma, sponsored by Virginia Commonwealth University.
NCT06989086 is a NA study of Caregiver and Astrocytoma that is actively recruiting participants, run by Virginia Commonwealth University. The registered enrollment target is 112 participants, below the 1,251-participant average among 20 other Caregiver trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06989086, a NA study of Caregiver and Astrocytoma, is actively recruiting participants, sponsored by Virginia Commonwealth University.
- RECRUITING
- Registry status
- NA
- Development phase
- 112 participants
- Enrollment target
- 1
- Study location
Study Summary
The overarching goal of this project is to assess the feasibility, acceptability, and appropriateness of recruitment methods, target population, and a waitlist design to finalize the protocol of FearLess in primary malignant brain tumor patients and caregivers
Primary Outcome
Feasibility of study enrollment using a multimodal recruitment approach will be assessed by comparing observed rates of screening completion, trial eligibility, trial enrollment (i.e., informed consent), and randomization allocation to pre-specified benchmarks.
Conditions Studied
Interventions
- BEHAVIORAL Fearless in Neuro-Oncology
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2025-06-24 |
| Est. Completion | 2028-12-31 |
| Phase | NA |
What NCT06989086 shows while recruiting
NCT06989086 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 1,251-participant average among 20 other Caregiver trials with a reported enrollment target (91% lower).
The record links to 5 conditions, with Caregiver appearing as the primary indexed condition, and to 1 intervention - of which Fearless in Neuro-Oncology is the first listed.
NCT06989086 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06989086 about?
NCT06989086 is a clinical study titled "FearLess in NeuroOncology". The overarching goal of this project is to assess the feasibility, acceptability, and appropriateness of recruitment methods, target population, and a waitlist design to finalize the protocol of FearLess in primary malignant brain tumor patients and caregivers
What is the current status of trial NCT06989086?
This trial is currently recruiting. It is a NA study. The enrollment target is 112 participants. The study started on 2025-06-24. Estimated completion is 2028-12-31.
What conditions does trial NCT06989086 study?
This clinical trial studies the following conditions: Caregiver, Astrocytoma, Oligodendroglioma, Glioblastoma (GBM), Primary Malignant Brain Tumor.
What interventions are being tested in trial NCT06989086?
The interventions under investigation include: Fearless in Neuro-Oncology (BEHAVIORAL).
Who is sponsoring clinical trial NCT06989086?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06989086 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Caregiver
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06989086's enrollment target sits among peer trials
112 13th of 20 higher than 8 of 20 other Caregiver trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Caregiver trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Behavioral Health Program for Short-Stay Nursing Facility Residents & Care Partners
RECRUITING · NA
-
Support for Bereaved Cancer Caregivers
RECRUITING · NA
-
The REACH Intervention for Caregivers of Veterans and Service Members With TBI
RECRUITING · NA
-
mHealth for Early Psychosis Caregivers in Statewide Program Outreach
RECRUITING · NA
-
Multimedia Self-Management Intervention for Lung Cancer Surgery Family Caregivers and Patients
ACTIVE NOT RECRUITING · NA
-
Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their Caregivers Who Are Seen in the Outpatient Supportive/Palliative Care Center
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI